Compare LHX & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LHX | BDX |
|---|---|---|
| Founded | 1895 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5B | 55.1B |
| IPO Year | N/A | 1962 |
| Metric | LHX | BDX |
|---|---|---|
| Price | $288.64 | $196.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 9 |
| Target Price | ★ $298.63 | $213.13 |
| AVG Volume (30 Days) | 1.2M | ★ 2.2M |
| Earning Date | 01-29-2026 | 02-04-2026 |
| Dividend Yield | 1.67% | ★ 2.15% |
| EPS Growth | ★ 46.76 | N/A |
| EPS | ★ 9.29 | 5.82 |
| Revenue | $21,740,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $4.06 | $4.00 |
| Revenue Next Year | $6.00 | $3.40 |
| P/E Ratio | ★ $30.94 | $33.61 |
| Revenue Growth | 2.83 | ★ 8.24 |
| 52 Week Low | $193.09 | $162.29 |
| 52 Week High | $308.12 | $251.99 |
| Indicator | LHX | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.00 | 55.78 |
| Support Level | $277.57 | $188.52 |
| Resistance Level | $290.64 | $202.75 |
| Average True Range (ATR) | 6.11 | 3.82 |
| MACD | 0.94 | -0.13 |
| Stochastic Oscillator | 79.82 | 56.22 |
In addition to its legacy software-defined radio franchise, L3Harris Technologies has through a series of acquisitions established franchises producing uncrewed aerial vehicles, sensors, avionics, space-based systems, missiles, and solid rocket motors. It also adapts civilian aircraft for military use and provides military and commercial training services, and maintains the US Federal Aviation Administration's communications infrastructure.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.